All eyes on acquired assets

Similar documents
Ambuja Cement. Realisations-driven beat SELL RESULTS REVIEW 2QCY17 25 JUL Highlights of the quarter

Strong volumes, offset by costs

Weak numbers in peak quarter

Ambuja Cement. Weak numbers SELL RESULTS REVIEW 1QCY17 01 MAY 2017

BLS International Services

Healty cigarette-driven growth

Jubilant FoodWorks NEUTRAL RESULTS REVIEW 4QFY17 30 MAY Highlights of the quarter

Crompton Greaves Consumer Electricals

Jubilant FoodWorks BUY RESULTS REVIEW 1QFY18 18 JULY Highlights of the quarter

Near-term pressure, but long-term outlook positive

Crompton Greaves Consumer Electricals

Discounting $45/bbl of realisation

Multi Commodity Exchange

Marico Kaya BUY RESULTS REVIEW 4QFY15 29 APR 2015

Intellect Design Arena

Navin Fluorine International

BHEL SELL RESULTS REVIEW 1QFY15 13 AUG CMP (as on 12 Aug 2014) Rs 224 Target Price Rs 188

J. Kumar Infraprojects

Neuland Labs BUY RESULTS REVIEW 1QFY19 12 AUG 2018

PI Industries BUY RESULTS REVIEW 1QFY19 07 AUG Highlights of the quarter

NRB Bearings. Strong Show BUY RESULTS REVIEW 4QFY18 23 MAY Highlights of the quarter

Cement, Metals & Mining

Ahluwalia Contracts. Cautious optimism BUY RESULTS REVIEW 4QFY17 31 MAY Highlights of the quarter

Tata Steel. JV comes to fruition BUY COMPANY UPDATE 21 SEP Other key highlights. CMP (as on 20 Sep 17) Rs 688 Target Price Rs 818

Gulf Oil Lubricants BUY RESULTS REVIEW 1QFY19 09 AUG Key highlights

Hindustan Petroleum Corporation

Central Depository Services

Agrochemicals. 3QFY18E Results Preview 09 JAN Basanth Patil

Torrent Pharma BUY RESULTS REVIEW 1QFY18 01 AUG 2017

Carborundum Universal

Capital Goods. 3QFY18E Results Preview. 10 Jan Sujit Jain

Maruti Suzuki. A Trough Quarter BUY RESULTS REVIEW 3QFY19 25 JAN CMP(as on 25 Jan 2019) Rs 6,516 Target Price Rs 7,400

Vinati Organics BUY RESULTS REVIEW 2QFY19 29 OCT INDUSTRY CHEMICALS CMP (as on 29 Oct 2018) Rs 1,408 Target Price Rs 1,700

Coal India. Tough times BUY COMPANY UPDATE 22 AUG CMP (as on 21 Aug 17) Rs 238 Target Price Rs 300

Sun Pharma BUY RESULTS REVIEW 1QFY19 16 AUG 2018

Hindustan Petroleum Corporation

Central Depository Services

Alkem Labs BUY RESULTS REVIEW 1QFY19 11 AUG story remains on-track. Maintain BUY with a revised TP of Rs 2,410 (24x FY20E EPS).

Hindustan Unilever BUY RESULTS REVIEW 4QFY17 18 MAY 2017

Central Depository Services

Mahanagar Gas BUY RESULTS REVIEW 1QFY19 01 AUG Highlights of the quarter. CMP (as on 1 Aug 2018) Rs 947 Target Price Rs 1,292

Geared for version 3.0

Agriculture. 4QFY18E Results Preview 13 APR Madhukar Ladha

Kalpataru Power Transmission

Real Estate. 3QFY19E Results Preview. 11 Jan Parikshit D Kandpal, CFA

Coromandel International

Bharat Petroleum Corporation

Alkem Labs BUY RESULTS REVIEW 3QFY19 09 FEB CMP (as on 08 Feb 2019) Rs 1,904 Target Price Rs 2,340. Highlights of the quarter

ICICI Prudential Life

Jubilant Life Sciences

Max Financial. Improving margins! BUY RESULTS REVIEW 4QFY18 30 MAY Highlights of the quarter

Cyient. Good show, priced in NEUTRAL RESULTS REVIEW 4QFY17 21 APRIL Highlights of the quarter

Navin Fluorine International

Reliance Industries. Timing is everything BUY COMPANY UPDATE 1 OCT 2014

Exide Industries BUY RESULTS REVIEW 4QFY18 08 MAY Highlights of the quarter. CMP (as on 08 May 2018) Rs 268 Target Price Rs 298

Bajaj Auto BUY RESULTS REVIEW 1QFY18 21 JUL Highlights of the quarter

J. Kumar Infraprojects

Bajaj Auto NEUTRAL RESULTS REVIEW 2QFY16 23 OCT Key highlights. CMP (as on 23 Oct 2015) Rs 2,514 Target Price Rs 2,720

Sonata Software. On growth path BUY RESULTS REVIEW 1QFY18 16 AUG Highlights of the quarter

Bharti Infratel BUY RESULT REVIEW 3QFY19 25 JAN 2019

Music Broadcast. In-line but muted BUY RESULTS REVIEW 2QFY19 26 OCT Key highlights. CMP (as on 26 Oct 2018) Rs 328 Target Price Rs 387

Hero MotoCorp BUY RESULTS REVIEW 2QFY19 16 OCT CMP (as on 16 Oct 2018) Rs 2,898 Target Price Rs 3,602. Highlights of the quarter

Dishman Carbogen Amcis

Dilip Buildcon. Strong comeback BUY RESULT REVIEW 1QFY19 16 AUG Highlights of the quarter. CMP (as on 16 Aug 2018) Rs 847 Target Price Rs 1,434

Suprajit Engineering. Synergies to accrue BUY COMPANY UPDATE 16 SEP 2016

Subros BUY RESULTS REVIEW 2QFY19 30 OCT CMP (as on 29 Oct 2018) Rs 268 TP Rs 435. Key highlights

NIIT Technologies. NEUTRAL Higher capex weighing on FCF RESULTS REVIEW 2QFY15 16 OCT 2014

Dr. Reddy s Labs. Misery continues SELL RESULTS REVIEW 1QFY18 28 JUL 2017

Pre-sales pickup key trigger

PSP Projects. Marginal miss BUY RESULTS REVIEW 1QFY19 10 AUG 2018

Crompton Greaves Consumer Electricals

Hexaware Technologies

Insecticides India BUY RESULTS REVIEW 4QFY17 30 MAY 2017

ITC BUY RESULTS REVIEW 1QFY19 27 JUL 2018

Brigade Enterprises. Stable performance BUY RESULTS REVIEW 2QFY19 14 NOV 2018

Multi Commodity Exchange

The acquired plants operations are more profitable than BCORP s given the brand equity, RM linkage and high pricing in Bihar/WB markets.

JBM Auto. Ready to take off BUY RESULTS REVIEW 1QFY19 07 AUG Key highlights

Mphasis. Growth drivers intact BUY RESULTS REVIEW 3QFY19 25 JAN 2019

Radico Khaitan BUY RESULTS REVIEW 3QFY19 24 JAN 2019

Real Estate. 4QFY17E Results Preview. 13 Apr Parikshit D Kandpal

Emami NEUTRAL RESULTS REVIEW 4QFY15 14 MAY 2015

Bharat Forge. Cyclical headwinds persist but structural story intact BUY COMPANY UPDATE 9 DEC Key takeaways

Construction. 4QFY18E Results Preview 14 APR Parikshit D Kandpal

Lupin BUY COMPANY UPDATE 12 SEP 2013

Oil & Gas. 4QFY17E Results Preview. 13 Apr Deepak Kolhe

Thangamayil BUY RESULTS REVIEW 2QFY19 15 NOV 2018

Chemicals and Fertilisers

V-Guard BUY RESULTS REVIEW 3QFY19 02 FEB 2019

Weak quarter but well placed

Growth + cash flows = BUY

Outperformance continues

Mindtree. Steady quarter, Upside capped NEUTRAL RESULTS REVIEW 4QFY19 18 APR INDUSTRY CMP (as on 16 Apr 2019) Rs 972 Target Price Rs 1,040

FIRSTSOURCE SOLUTIONS LTD.

Margin boost through non-core book

IRB Infrastructure Developers

BUY. White cement steals the show JK CEMENT. Target Price: Rs 1,220. Other highlights

ITD Cementation (India) Ltd.

Brigade Enterprises BUY RESULTS REVIEW 2QFY16 03 NOV Highlights of the quarter. CMP (as on 03 Nov 2015) Rs 162 Target Price Rs 210

V-Guard. On track BUY COMPANY UPDATE 27 SEP 2017

Transcription:

INDUSTRY CEMENT CMP (as on 19 Jul 2017) Rs 4,206 Target Price Rs 3,763 Nifty 9,900 Sensex 31,955 KEY STOCK DATA Bloomberg UTCEM IN No. of Shares (mn) 275 MCap (Rs bn) / ($ mn) 1,155/17,947 6m avg traded value (Rs mn) 1,072 STOCK PERFORMANCE (%) 52 Week high / low Rs 4,533 / 3,050 3M 6M 12M Absolute (%) 6.8 21.5 19.9 Relative (%) (2.2) 4.5 4.9 SHAREHOLDING PATTERN (%) Promoters 62.14 FIs & Local MFs 5.52 FPIs 21.89 Public & Others 10.45 Source : BSE Ankur Kulshrestha, CFA ankur.kulshrestha@hdfcsec.com +91-22-6171 7346 Meera Midha meera.midha@hdfcsec.com +91-22-6171 7334 All eyes on acquired assets UltraTech Cement (UTCEM) delivered strong profitability (EBITAD/t: Rs 1,183, 6.1% YoY, 30.2% QoQ), mainly owing to higher pricing (Rs 5,026/t, 7.3% QoQ, 7.2% YoY). Volumes were flat (13.2 mt),with domestic sales witnessing a 1% decline. With JPA capacities (17.2 mtpa operational) in the bag, volume growth will resume from 2QFY18. However, JPA s capacities, operating at 15% in 1QFY18, are likely to drag down profitability too. UltraTech has guided for cash break-even in the fourth quarter of operations (1QFY19), and utilisation of 70% by then. We believe a cash breakeven is possible, but remain skeptical on utilisations, given the lack of clarity on Bara (4.0 mtpa grinding) and JP Super (2.3 mtpa clinker), both under commissioning. UTCEM remains expensive (17.9/13.8x FY18/19E EV/EBITDA) on modest return expectations (13.0/14.2% RoE in FY18/19E). We build in EBITDA/t of Rs 360/921 from the acquired units in FY18/19E. RESULTS REVIEW 1QFY18 20 JUL 2017 UltraTech Cement SELL Our revised TP stands at Rs 3,763 (12.0x June 19 EV/EBITDA, USD199/t. Highlights of the quarter P&F costs (32% YoY, 12.5% QoQ) continue to harden, as petcoke pricing finally impacts. (~58% up YoY). Proportion of petcoke in the overall mix remains high, and further gains will likely accrue only from acquired capacities scaling up their petcoke usage. Overall operational costs (Rs 3,843/t, 7.7% YoY, 1.7% QoQ) hardened too, offsetting a large part of the pricing gains. Near-term outlook: Cement prices continue to remain strong, with adjustments owing to GST (~3-4% or Rs 10-15) in most regions. However, demand is likely to dip now, given the strong onset of monsoon. Continuing issues with sand availability in some key states (UP, Punjab, Tamil Nadu) and drought will further weigh on demand. Financial Summary (Standalone) (Rs mn) 1QFY18 1QFY17 YoY(%) 4QFY17 QoQ(%) FY16 FY17 FY18E FY19E FY20E Net Sales 66,265 61,823 7.2 65,953 0.5 234,402 236,157 315,519 381,068 435,430 EBITDA 15,601 14,225 9.7 12,782 22.1 49,615 54,907 72,446 91,241 106,137 PAT 8,906 7,576 17.6 7,784 14.4 24,641 27,112 33,122 40,399 53,546 Diluted EPS (Rs) 32.19 27.61 16.6 21.81 47.6 86.4 96.2 120.6 147.1 195.0 P/E (x) 48.7 43.7 34.9 28.6 21.6 EV / EBITDA (x) 24.0 21.1 17.9 13.8 11.3 RoE (%) 11.5 11.6 13.0 14.0 16.2 HDFC securities Institutional Research is also available on Bloomberg HSLB <GO>& Thomson Reuters

Quarterly Financials Snapshot (Rs mn) 1QFY18 1QFY17 YoY (%) 4QFY17 QoQ (%) Net Sales 66,265 61,823 7.2 65,953 0.5 Power & Fuel 12,174 9,237 31.8 11,543 5.5 Freight Expenses 15,880 15,452 2.8 16,645 (4.6) RM Costs 10,228 10,010 2.2 10,666 (4.1) Other Operating Expenses 12,383 13,402 (7.6) 14,316 (13.5) EBITDA 15,601 14,225 9.7 12,782 22.1 Other Income 1,652 1,504 1,023 Interest Cost 1,285 1,525 (15.7) 1,189 8.0 Depreciation 3,098 3,027 3,357 PBT 12,870 11,177 15.1 10,160 26.7 Tax 3,963 3,428 3,276 RPAT 8,906 7,576 17.6 6,883 29.4 E/o 0 0 901 APAT 8,906 7,576 17.6 7,784 14.4 Note: Reported revenues/ebitda now inclusive of other op. inc. E/O Fourth consecutive quarter of flattish volumes, realisations drove the show. Costs now reflect the full impact of pet-coke pricing surge Per Tonne Analysis Per tonne data 1QFY18 1QFY17 YoY (%) 4QFY17 QoQ (%) Volumes (Blended, mt) 13.2 13.2 (0.1) 14.1 (6.3) Blended realisations (Rs/T) 5,026 4,684 7.3 4,689 7.2 P&F costs (Rs/T) 923 700 32.0 821 12.5 Freight costs (Rs/T) 1,204 1,171 2.9 1,183 1.8 RM costs (Rs/T) 776 758 2.3 758 2.3 Other costs (Rs/T) 939 1,015 (7.5) 1,018 (7.7) Cement EBITDA/T (Rs/t) 1,183 1,116 6.1 909 30.2 Costs 3,843 3,568 7.7 3,780 1.7 Page 2

Fourth consecutive quarter of flattish volumes, realisations drove the show. Costs now reflect the full impact of pet-coke pricing surge Key takeaways from the conference call Comments on demand Sector currently witnessing a demand shift to organised RE developers as a result of RERA imposition. Pressure in the IT sector likely to impact the new housing demand Rural markets are holding up well due to good sowing earlier on. Strong monsoons will help further Disbursement of HRA for 7 th Pay Commission may drive the demand from urban markets. At present, the housing segment seems to be declining by 2% give or take. Affordable housing should give it a fillip. UltraTech expects ~2 years for the organised RE to recover. Operational data Recent weakness in pet-coke prices. Petcoke remains attractive (USD 87-90 is the current price). Petcoke content is now at 60% in the energy mix. This can be taken to 75%. C:C ratio of UltraTech at 1.34 now. Capacity utilisation : North/West at 80%, east at 90%, South at 60%, Central at 70% On JPA assets Post acquisition, UTCEM is still operating the old brand (Jaypee Cement) in Central India. It sells Rs 15-20 below category A prices. JPA utilisation numbers for the last quarter should cross 60% by the end of FY18. Likely to see average realisations of 70% in 4th quarter of operations. Central region will witness the maximum improvement EBITDA of Rs 400/t in the operating assets currently. Large part of the EBITDA is driven by tax incentives (Please refer next page for complete list of incentives enjoyed by JPA) Petcoke composition can be increased significantly in the acquired plants. Limestone constraints in 1-2 plants, where the pet-coke content will be lower Cash breakeven by 4th quarter of operations Super Dalla to be operational sometime during the year Net debt at June end: Rs 128.7bn (standalone nos) - largely in line. Based on quick calculations it should have ended at Rs 125.7bn (Ending net cash Rs24.22bn less JPA acquisition (Rs 161.9bn) plus 1QFY18 PAT + depreciation (Rs 12.0bn). There is ~Rs 3bn expansion in working capital, going by these numbers. Page 3

Valuations continue to remain expensive. Grasim preferable vehicle of exposure UTCEM is expected to be the key beneficiary of a resurgent cement demand and we expect sharp volume growth Peer Valuation Company EV/EBITDA MCAP CMP TP P/E (x) EV/T (US$) RoE (%) Reco. (x) (Rs. bn) (Rs) (Rs) FY18E FY19E FY18E FY19E FY18E FY19E FY18E FY19E Ultratech Cement 1,155.1 4,206 SELL 3,763 34.9 28.2 17.9 13.8 285 237 13.0 14.2 Shree Cement 636.1 18,257 SELL 14,565 53.5 34.8 22.8 15.7 264 240 15.7 20.4 Ambuja Cement 1 523.9 265 SELL 200 38.3 27.2 15.5 11.5 172 165 17.4 21.8 ACC Ltd 1 326.4 1,735 SELL 1,459 30.1 22.2 15.7 12.2 145 141 11.2 14.8 Ramco Cements 165.7 696 SELL 690 22.7 20.5 13.7 12.1 204 195 18.1 17.3 Birla Corp 72.0 935 NEU 1,005 40.5 27.3 12.8 11.0 120 114 5.3 7.5 Orient Cement 32.7 160 NEU 165 44.4 15.1 11.6 8.4 72 69 5.8 13.1 Sanghi Industries 21.2 96 BUY 98 12.6 7.9 6.9 4.8 96 86 14.0 18.9 Note: Prices as of July 19, 2017 close. US$: INR = 65 1 December YE Key Assumptions Year Ending June FY16 FY17E FY18E FY19E FY20E Clinker Utilisation 76% 76% 62% 64% 71% Blended Volumes 49.3 50.2 59.4 70.8 77.5 Ultratech Standalone 49.3 50.2 52.9 56.2 62.1 Acquired Ops 6.5 13.3 15.4 Blended Realisations 4,632 4,706 5,316 5,484 5,616 Ultratech Standalone 4,632 4,706 4,957 5,205 5,387 Acquired Ops 4,573 4,750 4,752 P&F Cost/Tonne 860 782 810 744 731 Raw Material Cost/Tonne 810 787 772 748 779 Freight Cost/Tonne 1,037 979 1,093 1,072 1,152 EBITDA/Tonne 884 935 1,144 1,241 1,298 Ultratech Standalone 884 935 1,240 1,317 1,368 Acquired Ops 358 921 1,013 Cost/Tonne 3,748 3,770 4,172 4,243 4,318 Page 4

The acquired capacities have units whose commissioning will still take time Most levy assumptions run out in a short time Assets Included In The Transaction Location Plant Capacity (mtpa) Clinker Cement Dalla IC 2.1 0.5 JP Super* C 2.3 Tanda GU 1.0 Sikanderabad GU 1.0 Bara* GU 4.0 Bela IC 2.1 2.6 Sidhi IC 3.1 2.3 Satna Cluster 9.6 11.4 Baga IC 3.3 1.7 Bagheri GU 2.0 Roorkee GU 1.1 HP Cluster 3.3 4.8 Balaji IC 3.3 5.0 Shahabad GU 1.2 South Cluster 3.3 6.2 Total 16.2 22.4 * Under commissioning, IC: Integrated cement and clinker unit, C: Clinker only, GU Grinding unit Key Levy Exemptions Available To Jaypee Associates Capacity Plant Exemption (mtpa) Applicable till Remainder period (months) * Dalla 0.5 10-year refund on VAT/CST Jan-18 7 Dalla 0.5 Exemption on payment of royalty on limestone Jan-18 7 Bahgeri 0.5 VAT Deferment Mar-18 9 Sidhi 2.3 Refunds of 75% of VAT/CST deposited Feb-19 20 Tanda 1.0 Interest free VAT loan Oct-19 28 Roorkee 1.1 Excise exemption Dec-19 30 Bagheri 2.0 Excise exemption Jan-20 31 Baga 1.7 Excise duty exemption Feb-20 33 Baga 1.7 VAT/CST exemption Feb-20 33 Sikandrabad 1.0 Interest free VAT loans Apr-26 108 Page 5

Headline profitability at Rs 1,180/t, costs have flattened Volume growth remains sluggish Sales volume (mt) mnt 16.0 14.0 12.0 10.0 8.0 6.0 4.0 2.0 0.0 YoY% 20.0 15.0 10.0 5.0 - (5.0) Realisations improved across country 5,500 5,000 4,500 4,000 3,500 3,000 Blended realisations (Rs/T) YoY (%) Rs/T % 35.0 30.0 25.0 20.0 15.0 10.0 5.0 - (5.0) (10.0) (15.0) 1QFY12 3QFY12 1QFY13 3QFY13 1QFY14 3QFY14 1QFY15 3QFY15 1QFY16 3QFY16 1QFY17 3QFY17 1QFY18 1QFY12 3QFY12 1QFY13 3QFY13 1QFY14 3QFY14 1QFY15 3QFY15 1QFY16 3QFY16 1QFY17 3QFY17 1QFY18 EBITDA/t At Rs 1,183 EBITDA/T (Rs) YoY (%) 1,400 Rs/T % 1,200 1,000 800 600 400 200-80.0 60.0 40.0 20.0 - (20.0) (40.0) (60.0) Costs Have Flattened P&F costs/t Freight cost/t RM cost/t Emp cost/t Other exp/t 4,500 4,000 3,500 3,000 2,500 2,000 1,500 1,000 500-1QFY12 3QFY12 1QFY13 3QFY13 1QFY14 3QFY14 1QFY15 3QFY15 1QFY16 3QFY16 1QFY17 3QFY17 1QFY18 1QFY12 3QFY12 1QFY13 3QFY13 1QFY14 3QFY14 1QFY15 3QFY15 1QFY16 3QFY16 1QFY17 3QFY17 1QFY18 Page 6

Income Statement Year ending March (Rs mn) FY16 FY17 FY18E FY19E FY20E Net sales 234,402 236,157 315,519 381,068 435,430 Growth % 3.5 0.7 33.6 20.8 14.3 Material Expenses 100,712 98,516 115,145 125,949 140,793 Employee Expenses 13,430 14,134 15,955 17,551 19,306 SG&A Expenses 71,134 70,504 105,521 139,780 162,571 Other operating expenses 5,546 6,070 11,000 11,550 12,128 Operating profits 43,580 46,933 67,898 86,239 100,634 Operating Profit Margin (%) 18.6 19.9 21.5 22.6 23.1 Other operating income 6,034 7,974 4,548 5,003 5,503 EBITDA 49,615 54,907 72,446 91,241 106,137 EBITDA % 21.2 23.3 23.0 23.9 24.4 EBITDA Growth % 18.3 10.7 31.9 25.9 16.3 Depreciation 12,031 11,981 16,130 23,770 25,008 EBIT 37,584 42,926 56,316 67,471 81,129 Other Income (including EO items) 1,458 1,245 1,245 1,245 1,245 Interest 5,117 5,714 10,244 11,003 5,880 PBT 33,925 38,457 47,317 57,713 76,494 Tax 9,284 11,482 14,195 17,314 22,948 RPAT 24,641 26,975 33,122 40,399 53,546 EO (Loss) / Profit (Net Of Tax) 0-137 0 0 0 APAT 24,641 27,112 33,122 40,399 53,546 APAT Growth (%) 22.3 10.0 22.2 22.0 32.5 Adjusted EPS (Rs.) 86.4 96.2 120.6 147.1 195.0 EPS Growth (%) 17.6 11.3 25.4 22.0 32.5 Balance Sheet As at March (Rs mn) FY16 FY17 FY18E FY19E FY20E SOURCES OF FUNDS Share Capital 2,745 2,746 2,745 2,745 2,745 Reserves 213,574 236,665 266,483 303,578 353,820 Total Shareholders Funds 216,319 239,411 269,228 306,323 356,565 Long Term Debt 26,748 42,001 182,001 62,001 47,001 Short Term Debt 58,855 22,972 22,972 22,972 22,972 Total Debt 85,604 64,973 204,973 84,973 69,973 Deferred Taxes 24,320 27,736 27,736 27,736 27,736 Long Term Provisions & Others 2,538 3,080 3,080 3,080 3,080 TOTAL SOURCES OF FUNDS 328,780 335,199 505,017 422,112 457,354 APPLICATION OF FUNDS Net Block 230,942 235,205 380,965 392,195 377,187 CWIP 14,156 8,784 33,784 15,784 15,784 Investments 7,246 7,460 7,460 7,460 7,460 LT Loans and Advances 6,122 4,044 4,044 4,044 4,044 Total Non-current Assets 258,465 255,493 426,253 419,483 404,475 Inventories 22,776 22,250 25,726 27,616 33,152 Debtors 14,149 12,762 18,667 16,277 23,531 Other Current Assets 14,397 13,312 13,312 13,312 13,312 Cash & Equivalents 73,119 88,995 88,395 7,959 57,030 Total Current Assets 124,441 137,318 146,100 65,163 127,026 Creditors 15,815 17,138 26,862 22,059 33,672 Other Current Liabilities & Provns 38,312 40,474 40,474 40,474 40,474 Total Current Liabilities 54,126 57,612 67,336 62,533 74,146 Net Current Assets 70,315 79,706 78,764 2,630 52,879 TOTAL APPLICATION OF FUNDS 328,779 335,199 505,017 422,112 457,354 Page 7

Cash Flow Year ending March (Rs mn) FY16 FY17 FY18E FY19E FY20E Reported PBT 32,986 37,760 47,317 57,713 76,494 Non-operating & EO items 1,991 (1,382) (1,245) (1,245) (1,245) Interest expenses 5,117 5,714 10,244 11,003 5,880 Depreciation 12,031 11,981 16,130 23,770 25,008 Working Capital Change 1,367 5,783 342 (4,302) (1,178) Tax paid (9,284) (11,482) (14,195) (17,314) (22,948) OPERATING CASH FLOW ( a ) 44,206 48,373 58,593 69,625 82,011 Capex (19,728) (11,079) (186,890) (17,000) (10,000) Free cash flow (FCF) 24,478 37,294 (128,297) 52,625 72,011 Investments (26) (214) 0 0 0 Non-operating Income 1,425 1,382 1,245 1,245 1,245 INVESTING CASH FLOW ( b ) (18,329) (9,911) (185,645) (15,755) (8,755) Debt Issuance/(Repaid) 4,168 (20,631) 140,000 (120,000) (15,000) Interest expenses (5,117) (5,714) (10,244) (11,003) (5,880) FCFE 23,530 10,950 1,460 (78,377) 51,131 Share Capital Issuance 0 0 0 0 0 Dividend (3,138) (3,304) (3,304) (3,304) (3,304) FINANCING CASH FLOW ( c ) (4,086) (29,648) 126,453 (134,306) (24,184) NET CASH FLOW (a+b+c) 21,792 8,814 (600) (80,436) 49,072 EO Items/Others Closing Cash & Equivalents 73,114 81,933 88,395 7,959 57,030 Key Ratios FY16 FY17 FY18E FY19E FY20E PROFITABILITY (%) EBITDA Margin 21.2 23.3 23.0 23.9 24.4 APAT Margin 10.5 11.5 10.5 10.6 12.3 RoE 11.5 11.6 13.0 14.0 16.2 Core RoCE 14.8 16.5 14.3 13.2 16.2 RoCE 11.2 11.6 11.0 11.7 14.9 EFFICIENCY Tax Rate (%) 28.1 30.4 30.0 30.0 30.0 Asset Turnover (x) 0.8 0.8 0.8 0.8 0.9 Inventory (days) 36 33 26 23 22 Debtors (days) 16 18 16 15 15 Payables (days) 21 21 19 21 21 Cash Conversion Cycle (days) 31 30 23 17 16 Debt/EBITDA (x) 1.9 1.6 2.0 1.7 0.8 Net D/E 0.1-0.1 0.4 0.3 0.0 Interest Coverage 7.4 7.6 5.6 6.2 14.0 PER SHARE DATA EPS (Rs/sh) 86.4 96.2 120.6 147.1 195.0 CEPS (Rs/sh) 130.2 139.4 179.4 233.8 286.2 DPS (Rs/sh) 9.5 10.0 10.0 10.0 10.0 BV (Rs/sh) 788.4 872.1 980.8 1115.9 1298.9 VALUATION P/E 48.7 43.7 34.9 28.6 21.6 P/BV 5.3 4.8 4.3 3.8 3.2 EV/EBITDA 24.0 21.1 17.9 13.8 11.3 OCF/EV (%) 3.7% 4.1% 5.1% 6.1% 6.7% FCF/EV (%) 2.1% 3.2% -11.2% 4.6% 5.9% FCFE/Market Cap (%) 2.0% 0.9% 0.1% -6.8% 4.4% Dividend Yield (%) 0.2 0.2 0.2 0.2 0.2 Page 8

RECOMMENDATION HISTORY Ultratech 4,600 4,400 4,200 4,000 3,800 3,600 3,400 TP Date CMP Reco Target 20-Jul-16 3,560 NEU 3,200 7-Oct-16 3,960 NEU 3,931 18-Oct-16 4,013 NEU 3,931 23-Jan-17 3,528 NEU 3,380 13-Apr-17 4,033 SELL 3,380 26-Apr-17 4,242 SELL 3,380 20-Jul-17 4,206 SELL 3,763 3,200 3,000 Rating Definitions 2,800 Jul-16 Aug-16 Sep-16 Oct-16 Nov-16 Dec-16 Jan-17 Feb-17 Mar-17 Apr-17 May-17 Jun-17 Jul-17 BUY : Where the stock is expected to deliver more than 10% returns over the next 12 month period NEUTRAL : Where the stock is expected to deliver (-)10% to 10% returns over the next 12 month period SELL : Where the stock is expected to deliver less than (-)10% returns over the next 12 month period Page 9

Disclosure: We, Ankur Kulshrestha, PGDBM & Meera Midha, IDM, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. HSL has no material adverse disciplinary history as on the date of publication of this report. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. Research Analyst or his/her relative or HDFC Securities Ltd. does not have any financial interest in the subject company. Also Research Analyst or his relative or HDFC Securities Ltd. or its Associate may have beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of the Research Report. Further Research Analyst or his relative or HDFC Securities Ltd. or its associate does not have any material conflict of interest. Any holding in stock No HDFC Securities Limited (HSL) is a SEBI Registered Research Analyst having registration no. INH000002475. Disclaimer: This report has been prepared by HDFC Securities Ltd and is meant for sole use by the recipient and not for circulation. The information and opinions contained herein have been compiled or arrived at, based upon information obtained in good faith from sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. This document is for information purposes only. Descriptions of any company or companies or their securities mentioned herein are not intended to be complete and this document is not, and should not be construed as an offer or solicitation of an offer, to buy or sell any securities or other financial instruments. This report is not directed to, or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity who is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject HSL or its affiliates to any registration or licensing requirement within such jurisdiction. If this report is inadvertently send or has reached any individual in such country, especially, USA, the same may be ignored and brought to the attention of the sender. This document may not be reproduced, distributed or published for any purposes without prior written approval of HSL. Foreign currencies denominated securities, wherever mentioned, are subject to exchange rate fluctuations, which could have an adverse effect on their value or price, or the income derived from them. In addition, investors in securities such as ADRs, the values of which are influenced by foreign currencies effectively assume currency risk. It should not be considered to be taken as an offer to sell or a solicitation to buy any security. HSL may from time to time solicit from, or perform broking, or other services for, any company mentioned in this mail and/or its attachments. HSL and its affiliated company(ies), their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions. HSL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc. HSL and other group companies, its directors, associates, employees may have various positions in any of the stocks, securities and financial instruments dealt in the report, or may make sell or purchase or other deals in these securities from time to time or may deal in other securities of the companies / organizations described in this report. HSL or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months. HSL or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from t date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction in the normal course of business. HSL or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither HSL nor Research Analysts have any material conflict of interest at the time of publication of this report. Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. HSL may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report. Research entity has not been engaged in market making activity for the subject company. Research analyst has not served as an officer, director or employee of the subject company. We have not received any compensation/benefits from the subject company or third party in connection with the Research Report. HDFC securities Limited, I Think Techno Campus, Building - B, "Alpha", Office Floor 8, Near Kanjurmarg Station, Opp. Crompton Greaves, Kanjurmarg (East), Mumbai 400 042 Phone: (022) 3075 3400 Fax: (022) 2496 5066 Compliance Officer: Binkle R. Oza Email: complianceofficer@hdfcsec.com Phone: (022) 3045 3600 HDFC Securities Limited, SEBI Reg. No.: NSE-INB/F/E 231109431, BSE-INB/F 011109437, AMFI Reg. No. ARN: 13549, PFRDA Reg. No. POP: 04102015, IRDA Corporate Agent License No.: HDF 2806925/HDF C000222657, SEBI Research Analyst Reg. No.: INH000002475, CIN - U67120MH2000PLC152193 Mutual Funds Investments are subject to market risk. Please read the offer and scheme related documents carefully before investing. Page 10

HDFC securities Institutional Equities Unit No. 1602, 16th Floor, Tower A, Peninsula Business Park, Senapati Bapat Marg, Lower Parel, Mumbai - 400 013 Board : +91-22-6171 7330 www.hdfcsec.com Page 11